Cormedix

CORMEDIX INC

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Santa,Clara,,California,-,April,26,,2018:,Applied,Materials,Offices

News

Price Target

Markets

Analyst Ratings

Trading Ideas

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

CorMedixMunich,,Bavaria,,Germany,-,March,31,2023:,Cormedix,Is,A

Movers

CorMedix Inc (NASDAQ:CRMD) shares are hitting new 52-week highs on Monday after the company raised its sales guidance for the second quarter.

CorMedix Stock Hits New 52-Week High On Updated Guidance: The Details

Scottsdale,,Arizona,-,Aug.,08,2023:,A,New,Tesla,Optimus

Intraday Update

AIRO

CRCL

EPSM

EXEL

MANU

NTRS

OUST

SANA

SCHL

SPTN

TSLA

ZETA

Tesla, SpartanNash, Standard BioTools And Other Big Stocks Moving Higher On Monday

Cormedix Inc

Legal

Press Releases

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

Earnings

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

CorMedix Inc. to Participate in the RBC Global Healthcare Conference

CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference

General

CorMedix inc. Announces Customer Implementation

Amylyx Pharmaceuticals, Inc. - Common Stock

Amylyx Pharmaceuticals

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

ANI Pharmaceuticals

Arvinas

Collegium Pharmaceutical, Inc. - Common Stock

Collegium Pharmaceutical

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Evolus

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

EyePoint Pharmaceuticals, Inc. - Common Stock

EyePoint Pharmaceuticals

GH Research

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

Harrow

Innoviva

LENZ Therapeutics

Liquidia

Nuvation Bio

Ocular Therapeutix

Phibro Animal Health Corporation - Class A Common Stock

Phibro Animal Health

Pacira BioSciences

Phathom Pharmaceuticals, Inc. - Common Stock

Phathom Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Trevi Therapeutics

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences

Xeris Biopharma Holdings, Inc. - Common Stock

Xeris Biopharma Holdings

Needham

D. Boral Capital

RBC Capital

Leerink Partners

Comments

Cormedix

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell